Ironwood: Linzess Provides Temporary Relief Amid Apraglutide's Valuation Challenges
Ironwood Pharmaceuticals is navigating a complex landscape as Linzess offers short-term benefits, but Apraglutide's rNPV fails to close the valuation gap, raising investor concerns.
Editorial Staff 1 day ago